Guidelines for Submission of Post-approval Variations Medicines Applications

The guidelines outline requirements for submission of post-approval variation applications, which are categorized into major and minor variations. Major variations involve significant changes to the manufacturing process, quality control testing, or the finished pharmaceutical product. These changes include replacement or addition of a manufacturing site, change to quality control testing, change and/or addition of alternative manufacturers, and changes to excipients or inactive ingredients. The guidelines specify that a major variation dossier must include detailed information on the change, including the rationale, impact on product quality, and any necessary testing or validation. Section I of the guidelines outlines the requirements for major variation dossiers, including detailed information on the change, impact on product quality, and any necessary testing or validation. The section covers 18 different types of major variations, including changes to manufacturing sites, quality control testing, and excipients. Minor variations, on the other hand, involve less significant changes to the registered product. These changes include changes to local agents, names of finished pharmaceutical products, and company or party responsible for batch release. Minor variations also include changes to manufacturing processes, batch sizes, and specifications of APIs and excipients. The guidelines specify that minor variation dossiers must include a detailed description of the change, its impact on product quality, and any necessary testing or validation. Section II of the guidelines outlines the requirements for minor variation dossiers, including a detailed description of the change, its impact on product quality, and any necessary testing or validation. The section covers 24 different types of minor variations, including changes to local agents, names of finished pharmaceutical products, and company or party responsible for batch release. EFMHACA requires that all post-approval variation applications be submitted in accordance with the guidelines. The authority reviews each application to ensure that the proposed changes do not compromise the quality, safety, or efficacy of the registered product. The guidelines provide a framework for the submission of post-approval variation applications, ensuring that all necessary information is provided and that the proposed changes are thoroughly evaluated. The guidelines also specify that minor variations that do not require prior approval must be notified to EFMHACA within a specified timeframe. These variations include changes to the name and/or address of the marketing authorization holder, changes to the design or layout of packaging, and corrections to labeling or prescribing information. In summary, the guidelines for post-approval variations to registered medicines in Ethiopia provide a framework for the submission of post-approval variation applications, ensuring that all necessary information is provided and that the proposed changes are thoroughly evaluated. The guidelines categorize variations into major and minor variations, with different requirements for each category.